Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.

User "yungnickyyp" shares 5-month progress using Fin/Min/Niz/Derm for hair loss. Others express jealousy and amazement at the significant hair regrowth.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Pyrilutamide (KX-826) is being discussed as a potential hair loss treatment, with some users reporting no regrowth after three months. It may prevent further hair loss but might not promote regrowth unless combined with Minoxidil.

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

Combining finasteride with dutasteride may have additive benefits for reducing scalp DHT, but the extent is unknown. Some users report less shedding when using both treatments, with variations in dosage and application methods.

The user experienced hair loss after initially seeing positive results from using dutasteride and oral minoxidil. They are concerned about the hair shedding and wonder if stopping a multivitamin contributed to the issue.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

User "missbloombastic" has been experiencing hair loss since 2016 and tried min, fin, multivitamins, and spiro with mixed results. Another user shares their struggle with hair loss and its impact on self-esteem, while a third user suggests checking blood tests and confirming the cause of hair loss.

RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The user regrew their hairline using mechanical stimulation, including a 1.5mm derma roller weekly, daily scalp massages, and other treatments like Nizoral, zinc pyrithione, fish oil, and Lipogaine The Big 5. They did not use Minoxidil or finasteride.

The Derma Harmony Sulfur/Salicylic acid soap bar shampoo caused significant hair shedding, oily scalp, and cystic acne. The user experienced better results with rosemary shampoo.